Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cervical cancer, primarily caused by Human Papilloma Virus (HPV), is a significant global health concern, ranking as the fourth most common cancer in women worldwide. In Indonesia, it stands as the second most frequent cancer among women. This study investigates the performance of Cerviray® AI and Cerviray® AI Evaluation, an artificial intelligence (AI) technology for diagnosing cervical cancer, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC) with the Visual Inspection with Acetic Acid (VIA) test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)

NCT06452004

HPV Infection Cervix Cancer Cervical Dysplasia

ACTIVE_NOT_RECRUITING NA

Low-cost Imaging Technology for Global Prevention of Cervical Cancer

NCT05078528

Cervical Intraepithelial Neoplasia

RECRUITING NA

Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer

NCT04551287

Cervical Cancer Diagnostic Platform Diagnosing Cervical Cytology Grades and Cancer +1 more

COMPLETED

Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer

NCT06815939

Human Papillomavirus (HPV) Cervical Intraepithelial Neoplasia Uterine Cervical Neoplasms +1 more

RECRUITING NA

Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier

NCT04859530

Cervical Cancer HPV

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study involved 44 patients from various health centers in West Java Province. Cerviray® AI, Cerviray® AI Evaluation, and VIA tests were administered to high-risk women of childbearing age.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cerviray AI

Patient was screened using Cerviray AI, Cerviray AI evaluation by expert anc compared to VIA test in the same day.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* high-risk women of childbearing age who would be screened for cervical cancer (by Cerviray AI examination, Cerviray AI evaluation, and VIA test) at 1 clinic and other 4 health centers